Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Caffeine 200 mg Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Pre-Workout on Exercise Performance and Cognition

NCT02255201
View directory record Official record
Conditions
Healthy
Interventions
Master Performance Blend Dose 1, Master Performance Blend Dose 2, Performance Energy Blend, Energy Blend, Placebo
Dietary Supplement
Lead sponsor
Miami Research Associates
Network
Eligibility
18 Years to 40 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Lifestyle Factors on Neutrophil Migration Pilot Study

NCT02411318
View directory record Official record
Conditions
Neutrophil Chemotactic Response
Interventions
Exercise, ProLab 200mg caffeine capsule, Ethanol ingestion, Glucose Tolerance Drink
Behavioral · Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

NCT00826280
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, overencapsulated caffeine, technetium, placebo
Drug · Radiation
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

NCT05067439
View directory record Official record
Conditions
Healthy Participants
Interventions
Abrocitinib, Omeprazole, Caffeine, Efavirenz
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)

NCT00809471
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
placebo, avanafil
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

NCT01766050
View directory record Official record
Conditions
Transplant Rejection
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Belatacept
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Results available

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

NCT02688088
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Drug Cocktail, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine

NCT05811923
View directory record Official record
Conditions
Metabolic Syndrome, Caffeine
Interventions
Venous Blood Collection, Resting Metabolic Rate Determination, Mood State, Visual Analog Scales
Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

NCT02685462
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Atorvastatin, Simvastatin, Digoxin, Caffeine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

NCT00741468
View directory record Official record
Conditions
Drug Interactions
Interventions
Proellex, CYP1A2 probe, CYP2C9 probe, CYP2C19 probe, CYP2D6 probe, CYP3A4 probe
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Not applicable Interventional Results available

Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD

NCT00363298
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
dextro-amphetamine, Sham Comparison
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

NCT05657613
View directory record Official record
Conditions
Drug Interactions
Interventions
CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus

NCT06117280
View directory record Official record
Conditions
Energy, Focus, Caffeine Withdrawal
Interventions
Paraxanthine 200 mg, Paraxanthine 300 mg, Placebo
Other
Lead sponsor
Iovate Health Sciences International Inc
Industry
Eligibility
18 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 30, 2026, 2:58 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Study to Examine the Ability of a Caffeine-Based Energy Drink to Impact Energy Expenditure, Fat Oxidation, Reaction Time, and Other Perceptual Indicators

NCT05998096
View directory record Official record
Conditions
Energy Expenditure, Cognition, Reaction Time
Interventions
Caffeine-Based Energy Drink, Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 30, 2026, 2:58 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Caffeine on Chess Performance and Cognitive Function in Professional Chess Players

NCT07641335
View directory record Official record
Conditions
Cognitive Performance, Attention, Reaction Time, Caffeine
Interventions
Caffeinated Coffee, Decaffeinated Coffee Placebo
Dietary Supplement
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Sep 30, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

NCT01517399
View directory record Official record
Conditions
Solid Tumors
Interventions
tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam
Drug · Dietary Supplement
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Sep 30, 2026, 2:58 PM EDT